NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國醫藥研發承包商(CRO)行業分析(2020-2026)

China Contract Research Organization (CRO) Industry Report, 2020-2026

出版商 ResearchInChina 商品編碼 973124
出版日期 內容資訊 英文 202 Pages
商品交期: 最快1-2個工作天內
價格
中國醫藥研發承包商(CRO)行業分析(2020-2026) China Contract Research Organization (CRO) Industry Report, 2020-2026
出版日期: 2020年11月17日內容資訊: 英文 202 Pages
簡介

中國在藥品研發成本方面與發達國家相比具有很高的競爭力,吸引了許多主要的國際製藥公司,並發展了CRO(開發合同代理)行業。到2020年,中國CRO行業預計將以每年10.1%的速度增長,達到人民幣816億元的規模。如今,不僅外國關聯公司而且國內關聯公司都在顯著增長。近年來,該行業的主要動向包括公司併購(M&A)的增加,主要公司的連續上市以及垂直整合的進步。

本報告分析了中國藥品開發業務承包商(CRO)行業,分析了全球市場的歷史,結構和趨勢,中國的發展環境和歷史,行業的基本結構和背景以及整體情況。我們正在調查市場規模,競爭格局,近期發展趨勢,國內外主要公司的概況(業績,業務結構,戰略發展狀況等)趨勢。

目錄

第1章藥品外包概述

  • 定義
  • 分類
  • CRO(藥物開發業務承包商)

第2章全球CRO行業的發展趨勢

  • 工業發展史
  • 產業發展背景
    • 製藥業規模
    • 製藥公司的趨勢
    • 融資
    • 藥物研發(研發)
  • 市場規模
  • 競爭形勢

第3章中國的CRO行業

  • 開發環境
    • 法規
    • 政策環境
    • 行業環境
  • 當前狀態
  • 市場規模
  • 競爭形勢
  • 發展趨勢
    • 增加的研發成本負擔:製藥公司越來越依賴CRO公司進行新藥開發
    • 優惠的政策和資本投資:促進國內公司發展的因素
    • 廣闊的發展前景吸引了許多公司加入CRO行業
    • 行業垂直整合的進展
    • 合併/收購(M&A):潛力是CRO公司擴張的主要手段
    • 全面實施一致性評估為CRO行業提供了發展機會
    • 所需公司規模和行業集中度逐漸提高
    • 專業化和加強特定領域的運動變得更加清晰

第4章大型國內公司

  • Wuxi AppTec
  • Hangzhou Tigermed
  • Guangzhou Boji Pharmaceutical
  • Shanghai Meidicilon Inc.
  • Porton Fine Chemicals
  • Joinn Laboratories
  • Pharmaron
  • Obio Technology (Shanghai)
  • Nanjing Huawe Medicine Technology Group Co., Ltd.
  • Shanghai ChemPartner
  • HitGen Inc.
  • BioDuro
  • VIVA Biotech

第5章主要外國公司

  • LabCorp
  • IQVIA
  • Parexel
  • Charles River
  • PPD
  • Syneos Health
  • PRA
  • ICON
目錄

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the proliferating expenses for pharmaceutical R&D. In 2020, the world CRO market is expected to worth $69.9 billion with a year-on-year spike of 9%.

Competition ever pricks up among at least 1,100 CRO players worldwide led by LabCorp, IQVIA, Syneos, Parexel, PRA, PPD, and Charles River. In 2019, IQVIA, LabCorp and Syneos were the three leaders sweeping a combined market share of 21.5%.

China's great competitive edge over the developed countries in pharmaceutical R&D cost has allured many world-renowned pharmaceutical corporations and boosted the country's CRO industry. With speedy development over a decade, China has been an important CRO market whose market size in 2020 will soar 10.1% on an annualized basis and reach RMB81.6 billion.

In addition to multinational giants represented by IQVIA, LabCorp, Parexel, etc., China also sees local CRO leaders including Wuxi AppTec, Pharmaron, Meidicilon, Shanghai ChemPartner, Tigermed, and Joinn Laboratories, where Wuxi AppTec with the strongest R&D strength as one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs, not only runs the China's largest small-molecule pharmaceutical R&D service business but leads the way in global market. It enjoyed a virtually 12.3% (up 1.8 percentage points over the prior year) of the world's CRO market in 2019.

China's CRO industry will be heading towards:

  • 1) Mergers and acquisitions will still prevail for an industry reshuffle: Seen from the development course of multinational CRO companies, giants expand their business and sharpen edges through M&As, so do the Chinese CRO peers in recent year. In September 2020, Asymchem acquired the CRO company GoalGen for RMB30 million.
  • 2) Chinese CRO companies have landed in the capital market: WuXi AppTec and Pharmaron were listed on the A-share and H-share markets successively. In 2019, Viva Biotech went public on the Hong Kong Stock Exchange. In 2020, HitGen was listed on the A-share market.
  • 3) The industry gears toward vertical integration: Wuxi AppTec, for example, is able to provide customers with integrated new drug R&D and production services, which can help customers save plenty of time and costs as well as improve R&D and production efficiency. Noticeably, the players like Pharmaron, Boji Medical Biotechnological, Porton Pharma Solutions, and Shanghai ChemPartner are expanding to CMO/CDMO.

“China Contract Research Organization (CRO) Industry Report, 2020-2026” highlights:

  • Global CRO industry (development history/environment, market size, competitive landscape, etc.);
  • China CRO industry (development environment, status quo, market size, competition pattern, development trends, etc.);
  • 13 Chinese and 8 foreign companies (revenue, business structure, CRO business, etc.)

Table of Contents

1. Overview of Pharmaceutical Outsourcing

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 CRO

2. Evolution of Global CRO Industry

  • 2.1 Development History
  • 2.2 Development Background
    • 2.2.1 Pharmaceutical Industry Size
    • 2.2.2 Pharmaceutical Companies Development
    • 2.2.3 Financing
    • 2.2.4 Pharmaceutical R&D
  • 2.3 Market Size
  • 2.4 Competitive Landscape

3. CRO Industry in China

  • 3.1 Development Environment
    • 3.1.1 Regulation
    • 3.1.2 Policy Environment
    • 3.1.3 Industry Environment
  • 3.2 Status Quo
  • 3.3 Market Size
  • 3.4 Competitive Landscape
  • 3.5 Development Trend
    • 3.5.1 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
    • 3.5.2 Favorable policies and capital promote the development of local Chinese companies
    • 3.5.3 Good Prospects Attract the Enterprises' Access into CRO Industry
    • 3.5.4 The Industry Heads toward Vertical Integration
    • 3.5.5 M&A May Become the Main Way for CRO Companies to Expand
    • 3.5.6 The Comprehensive Implementation of Consistency Assessment Brings Development Opportunities to the CRO Industry
    • 3.5.7 Industry threshold and concentration degree rises gradually
    • 3.5.8 Specialization and characterization are becoming ever more obvious

4. Major Chinese Companies

  • 4.1 Wuxi AppTec
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 Major Clients
    • 4.1.6 R&D Investment
    • 4.1.7 CRO Business
    • 4.1.8 Development Strategy
  • 4.2 Hangzhou Tigermed
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D Investment
    • 4.2.6 Development Strategy
  • 4.3 Guangzhou Boji Pharmaceutical
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D Investment
    • 4.3.6 Development Strategy
  • 4.4 Shanghai Meidicilon Inc.
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D Investment
    • 4.4.6 Major Clients
    • 4.4.7 Development Strategy
  • 4.5 Porton Fine Chemicals
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 R&D Investment
    • 4.5.6 Major Clients
    • 4.5.7 Development Strategy
  • 4.6 Joinn Laboratories
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D Investment
    • 4.6.6 Major Clients
    • 4.6.7 Development Strategy
  • 4.7 Pharmaron
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D Investment
    • 4.7.6 Major Clients
    • 4.7.7 Development Strategy
  • 4.8 Obio Technology (Shanghai)
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 R&D Investment
    • 4.8.6 Major Clients
    • 4.8.7 Development Strategy
  • 4.9 Nanjing Huawe Medicine Technology Group Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Major Clients
    • 4.9.4 Main Business
    • 4.9.5 Development Strategy
  • 4.10 Shanghai ChemPartner
    • 4.10.1 Profile
    • 4.10.2 Operation
    • 4.10.3 Revenue Structure
    • 4.10.4 Gross Margin
    • 4.10.5 Main Business
  • 4.11 HitGen Inc.
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Revenue Structure
    • 4.11.4 Gross Margin
    • 4.11.5 R&D Investment
    • 4.11.6 Major Clients
  • 4.12 BioDuro
    • 4.12.1 Profile
    • 4.12.2 Development Course
    • 4.12.3 R&D Center
    • 4.12.4 Development Dynamics
  • 4.13 VIVA Biotech
    • 4.13.1 Profile
    • 4.13.2 Operation
    • 4.13.3 Revenue Structure
    • 4.13.4 Gross Margin
    • 4.13.5 R&D Investment

5 Major Foreign Companies

  • 5.1 LabCorp
    • 5.1.1 Profile
    • 5.1.2 Operation
    • 5.1.3 Revenue Structure
    • 5.1.4 CRO Business
    • 5.1.5 Development in China
  • 5.2 IQVIA
    • 5.2.1 Profile
    • 5.2.2 Operation
    • 5.2.3 Revenue Structure
    • 5.2.4 Development Strategy
    • 5.2.5 Development in China
  • 5.3 Parexel
    • 5.3.1 Profile
    • 5.3.2 Operation
    • 5.3.3 Revenue Structure
    • 5.3.4 Dynamics
    • 5.3.5 Development in China
  • 5.4 Charles River
    • 5.4.1 Profile
    • 5.4.2 Operation
    • 5.4.3 Revenue Structure
    • 5.4.4 Development in China
  • 5.5 PPD
    • 5.5.1 Profile
    • 5.5.2 Operation
    • 5.5.3 Revenue Structure
    • 5.5.4 Development in China
    • 5.5.5 Excel PharmaStudies
  • 5.6 Syneos Health
    • 5.6.1 Profile
    • 5.6.2 Operation
    • 5.6.3 Revenue Structure
    • 5.6.4 CRO Business
    • 5.6.5 Development in China
  • 5.7 PRA
    • 5.7.1 Profile
    • 5.7.2 Operation
    • 5.7.3 Revenue Structure
    • 5.7.4 Development in China
  • 5.8 ICON
    • 5.8.1 Profile
    • 5.8.2 Operation
    • 5.8.3 Revenue Structure
    • 5.8.4 Development in China